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Introduction 
Patients \Vith solid tumors or hcmatological malignancies often develop 
ancmia at diagnosis or in the course of the discase (Means et aL 1992; Beguin 
1996; Moliterno ct aL 1996; Groopman et aL 1999). Many studies have shown 
that recombinant human erythropoietin (rHEpo) therapy can amcliorate the 
anemia associated with cancer and chcmotherapy, rcduce the need for trans-
fusions and improve quality of life as well as \Vork capacity, However, as 
Jllany as 30-50% of the patients do not respond, even ta very high doses of 
rHEpo, lt is, therefore, important to be able to recognize and correct condi-
tions advcrscly alTecting response to rHEpo, in particular functional iron 
dcncicncy. Wh en no such particular condition can be identificd, it wouid also 
be or grcal intcrest to have at one's disposaI predictive algorithms or 
n:sponse. Thcreby patients can be sclcctcd on the basis of thcir probability 
tp aehicve ;1 gond rL'sponse tn Ire:ltment :Ind prolnnged incffective tise of an 
expellsivL' mediclItion call he avoidL'd in those p;l1icnts with a low proba-
hilily or respollsc. ln this paper. wc will revicw factors polentially allecting 
rcsponse ln rH Epo and comment on the use of predictive algorithms, 
Factors inflllcncing rcsponsc 10 rHlIEpo 
Criteria of rcspol1se 
Bcfore analyzing factors potentially affecting response to rHEpo, it is crit-
ical ta dcfinc response criteria, Various trials in miscellaneous indications 
have cmployecl very different response criteria, Trials emp10ying less strin-
gent criteria l'or dcfining rcsponsc arc very likely to report bcttcr outcomc, 
1. 1 H . ." ~~ lIlll 
Therdorc. uniform response critcria should bc proposcu for transfused and 
untransfused. severely or not severcly anemic cancer patients. However. 
these criteria should neccssarily be partly different when rHEpo is used for 
the prevention or the treatment of anemia (Table 1). Prevention means that 
rHEpo is used in a nonancmic patient to averl the occurrence of ancmia 
after chemothempy or other interventions. Treatment signifies that rHEpo is 
given to reverse an anemia prçscnl al diagnosis or c1evcloping in the course 
of the discase. Complete resÎ)onse should be dclined hy lhe abscnce or 
<lllemia. i.e. maintenance (prevention) or achievelllcnt (trcalment) of a 
normal hcmatocril. Whcn lrcating an <lncmia. ,1 major rcsponse delineates 
Ihe ;Il:hievclllcni 01':1 signilkalll imprOVCIllCll( apprtl<lching ;1 Ilormal sill1:l-
lion, whereas ,1 minor rCSpOJ1Sè corresponds 10 a lllL',lsurahlc Ihough lèss dra-
matie effecl: a major n:sponsc l'ail be dclillcd by the abolition of transfusion 
needs and a hematocrit incrcment greater than 6 percentage points (Jnd 
Table L Criteria of rcsponse to rHEpo 
'n'calment of ancmia 
• Completc rcsponsc 
- Normalize Hct/Hb value 
• Major respanse: ail criteria SllOU/d be fI/lfilled 
- No transfusion requircmcnl 
- Hel inercl11cnt:::: 6% (Hb inerclllcnt:::: 2g/JI) 
- Aehicvc Het;, 30% (!-lb;' lOg/di) 
• Minor rcsponsc: 011(' critaioll 
- Dcercase of transfusion nccJs :::: SlY% 
- Hel inercl11cnt:::: 6% bul Hel < 30% (Hb incrcl1lcnl:::: 2g/JI but I-Ib < lOg/JI) 
- Achicvc Hel:::: 30% but Het ineremcnt < 6 0ft) (I-Ib :::: lOg/di but Hb inercmcnt 
< 2gldl) 
• Failurc: olle critcrioll 
- I)ccreast: of transfusion needs < 50'XI 
.- 1 let incrt:IllL'nt < 6% and 1 let < 30'X) (1111 illcl"t:Illl'1l1 < 2g/dl illld lib < lOg/di) 
Prevention of ancmia 
Complete rt:spollsc 
- Mainl<lin normal I-Icl/Hb valuc 
• Major rcsponsc: ail criteria s!um!d /Je jit/ji//cd 
- No transfusion rcquircmcnt 
- Het dccrcl11cnt < 6% (Hb Jecrcmt:nt < 2g/ùl) 
• Minar rcsponsc: ail criteria shou/d be fl/(fillcd 
- No transfusion requircment [!-lb;' 8 g/dl] 
- Het deererncnt ;, 6% (Hb decremcnt ;, 2g/dl) 
• Failurc: 
- Transfusion [!-lb < 8g/dl] 
ll~"I<..II"11 ,II Il.''I'\III."'l !l' <..1,\1111"1"'1<"1111 
achicvel11ent of n hematocrÎt higher tl1<In ]O(Xl; a minar response corresponds 
to only one of the two last criteria or a redllction of transfusion requirements 
by at Icast 50%. V/hen rHEpo is givcn ta prevent anemia, a major responsc 
corresponds to a drop of the hcmatoerit by less than 6 percentage points and 
a minor responsc 10 a larger drop in hematocrit but without need for trans-
fusion (Hb > Sg/dl). 
'j'r('(/tmc'II' ",elU'dll/t'.\" 
Varyin)!. l'ales 01" n .. 's pO Il SL' ln rlll':po a!llOIl)!. studics also rd1cct diffcrellccs 
in dose. J'requL'ney ilild route of adminislriltion. duration or therapy and the 
forlll ol" erythropoiclin lIsed Crable 2). 
There is a clear dose-response effect with rHEpo and most studics in 
canccr patients have uscd doses in the range of 300-900 U/kg/wk, weil abovc 
those given to renal failurc patients. For instance, treatmcnt of ancmia in 
patients with adv,lIlccd gastrointestinal cancer was much more succcss[lIl 
with IOOOOU compared with 2000U t-i.w. (Glimelius et al. 1998). Similarly, 
daily doses of 5000U were more effective than lower doses and 10000U did 
not bring about further improvcment in anemie patients with myeloma or 
lymphoma (Cazzola et al. 1995). 111e more eonvcnient subcutaneous route of 
administration has been shown ta ensure more favorable pharmaeokineties 
(Macdougall et al. 1989) that translates into higher efficacy in rcnal failure 
patients (Paganini ct al. 1995). Most trials administered rBEpo thricc 
wcckly. a sehedule demonstrated ta be more efficient than daily injections in 
normal subjects (Breymann ct al. 1996). ln normal volunteers treated for one 
Illonlh. weekly injections have becn shown 10 producc crythropoielic 
rcsponses similar ta those achicved \Vith Li.w. sehedules (Cheung et al. 2000). 
Although once-weckly dosing has becn shawn to increase Hb, decrcase trans-
fusions ancl improve quality of life in a fashion analogous ta what is obtained 
\Vith thrice-wcekly administration (Gabrilovc ct al. 2000), the equivalcncc of 
the twu scheclules remaÎns to be proven in prospective trials. 
\Vhcreas 111cre is no known diffcrellce in the cfflcacy and sardy profile 
01 Epoctin-a. (Jansscn-Cilag). Epoclin-jl (Roche) or gcnc-activatcd Epoctin 
(!\vL'ntis), novel IO/lg-,lcting crythropoictin mo!ccuks Illtly i.Ilso considerahly 
prolong exposure 10 lhe aclive drug and thus impraye the crticacy of therapy 
with fc\Ver injections. One of thcse mokcuks, named novcl-erythropoiesis 
stimulating protein (NESP) or darbepoietin alfa (Amgen), has already 
been tcstcd in prospective clinical trials in renal failure or cancer patients 
(Macdougall 2000). 
111e duration of trcatment is of critical importance. In the largest trial 
published sa far, whereas there was no signifieant differencc in the rate of 
transfusions betwccn placebo and rI-IEpo-treatcd patients cluring the fIrst 
month of therapy. the cliffercnec bccamc highly signiflcant during the second 
_\1(1 l" j)L"glllll 






Faclors n.:laling ln rHEpo In..'tlllllCIlI 




• Type of rHEpo 
Factors rclaling 10 the patient 
• Âge 
• Scx 
Factors relaling to the dÎscase 
• Type of cancer 
• Marrow infiltration 






Marrow nccrosis or fibrosis x 
I-Iel11ophagocytosis x 
Folalc, 1.312, iron ucncicncy x 
Factors rclating to chemothcrapy 
• Type of chell1othcr;:lpy 
Platinul11 vs non~platinum 
Intcnsily of chclllothcrapy x 





• Surgcry x 
FUllctional iron dellciency 
• Caused by ACD x 










AI k,lSI 1.')()lJ/kg I.i.w. 
SC> IV 
\Ved;.ly ""' I.i.w. '! 
Necus al k<lSl 2-3 munths 
Long-acting Epo: Jess [rcqucnl 
dosing 
Unless massive (uCllte Icukcmia) 
Not dfcclivL: if intellsi!ieJ 
Chclllolhe]"apy 
Low platdct ctlunt 
I3leeJing + impaircu iron relcasc 
A lJllljo/" caI/sr.! oI Irl!a{lJu:n{ jilillire 
1 h:dlo. .. "lI\)11 \11 Il",,])()IJ.'-,l" lU l"l.\IIIIIIII\III""111I • li, 
and third nHlIlIhs of trcatmcnt (Ahels 1'J')2). In that trial also. thc dticacy of 
rHEpo appearcd to bc lowcr in cancer patients not treated with chemother-
apy lx:causc crythropoietin was givcn for a shortcr duration (and at a lowcr 
dose). This is due to the fact that expansion of the erythropoietie marrow 
in response to rHEpo is very graduai ancl achicves maximum aetivily only 
arter sevcral wceks or treatmcnt (Beguin ct al. 1995). The rcsponsc ratc can 
thus be further improved when patients are treatecl for 6 months or more 
(Hcnry et al. 1994). In orcier 10 maximize "time with response", it woulcl bc 
c:..lt:sirablt: to achieve a fasler respol1se. Whcther this call he achicved withoul 
tutal ("ost incrcase hy providillg higher doses of rI-JEpo for a short pcriod of 
limc (c.g. OIlC l11olllh) foJ[owcd hy lowcr maintenance doses !"emains to he 
dl' IlH )]1sl ra tcd. 
f) isc({sc-(f ssocÎu 1 C( / j(/('( 0 rs 
A Il li Illher of Illechanisllls can he involved in the pathogcncsis of ancmia asso-
ciated with cancer (Means et al. 1992; Beguin 1996; Moliterno et al. 1996) 
anù, thcrct'ore, intcri"crc \Vith rcsponse to rHEpo in individual patients 
(Table 2). Red cell loss may result l'rom hypersplenism, bloocl losses con-
secutive ta hemorrhage or iatrogenic phlcbotomy, and autoimmune or 
microangiopathic hemolysis. Red ccII procluction may be climinishecl by bone 
marrow infiltration, marrow nccrosis, hcmophagocytosis, myelotlbrosis, 
cleficiency of crythropoietic cofactors (folic acid, vitamin B12, iron), or infec-
tions. 1l1ese mechanisms of allemia are 111uch more prevalent in hematologic 
malignancies, but it is always important to identify them, because specific 
therapeutic intervention can he eITcctivc. I-Iowevcr, cancer-associatccl anemia 
is orten delineatcd hy the more general features of the so-callcd "anemÎa of 
chronie clisorders" (ACD). ACD is a cytokine-driven condition characterized 
by inadequate production of erythropoietin, inhibition of the proliferation 
of crythroid progenitor cells in the bone marrow and disturbances of iron 
utilization (Sears 1992; Means ct al. 1992). 
Thc patielll's hcm<llologic paramclers al basclinc may also he of im-
portance. Paticnts with morc sevcrc ancmia and morc nccds for transfusion 
presumably have a lowcr probability of achieving a largel hematoeril. l're-
trcatment hcmillocrit was <InÎmportant factor when rHEpo was given for tlle 
prcvention of anemia (Crawford ct al. 1994) but no longer whcn it was given 
al'ter anemia was well-established (Ludwig ct al. 1994). 111is has been very 
weil illustratecl in animal studies in whieh rHEpo was l1lueh more "efficient" 
when il was startecl before the administration of 5-FU, because it could then 
increase the hematocrit better while myelosuppression was not occurring yet 
(Matsumoto ct al. 1990). 
Other factors have been examinecl (Table 2). Age and sex have not been 
reportcd 10 innuence respollse. Except whcll therc is major invasion by 
".:" 
cancer cclls and limited residual normal henwtopoiesis, marrow involvemcnt 
by the tumor does not appear to limit the cflicacy or rHEpo (Abels 1992: 
Oster ct al, 1990), The type or tumor has generally not inlluenced thc 
rcsponse rate, provided that no other specifie IllcChanÎslll or ancmia is al 
work. Patients with multiple myeloma or low-grade Iymphoma apparcntly 
have similar response rates (Osterborg cl al, 1996: Cazzola et al, 1995). 
Although thcre wcre no apparent dirrerences bctwccn hematologic and non-
hematologic malignaneics in [he largest study publishcd (Abels 1992), there 
has bccn a suggestion that patients with bre<lst or colon cancer (Ludwig ct 
al. 199Ja), but not those with s'Iuaillous ccII eareinoilla (Ludwig ct al. 199Jb), 
m;,y rcspt)JHI Jess weil tl1;II1 P;l1Îl'1ltS witl1 myeIOlll;1. II()Wl'ver. tl1CSl' discl"l.:p-
ancies Illost likely relate 10 dirrl'rl'1lel'S i1l l'llclllollll'rapy dULllioll and Întcll-
sity <llllong thelll. 
C!JCl11oll!erlfpy-re!o!ed ft/cI( )rs 
Chemotherapy may also hampcr response (Table 2). Ancmia in cancer pa-
tients is orten causcd or aggravatcd by thcrapy with antineaplastic agents. In 
l'articulaI', treatment with platinum, but not with other chemotherapcLltic 
agents, has bccn associated with impairment of crythropoietin production 
(Wood et al. 1995). Patients who have been heavily pretreated with 
chemotherapy usually experience severe stem ccli damage that should con-
siderably intcrfere with response to rI-lE po. Indced, the poorer rcsponse 
obtained in patients with lower platelet counts probably just indicates that 
(Osterborg et al. 1996; Cazzola et al. 1995). 
For patients trcated concomitantly with ehclllother:.lpy. there is no 
markcd diffcrcncc between those rcceiving platinum-hascd rcgimens 
(Markman ct al. 1l)93~ Cascinu ct al. 191)4) and those rcceiving other !"orills 
or eheillotherapy (Cazzola ct al. 1 ~92: Osterbor~ et al. 1996: Cazzola ct al. 
1995). A Illulticcnter stlldy showed the ,ame I-Ib response (speed and mag-
nitude) in patients receiving platinlllll-hased vs other forllls or chelllotherapy 
(i'awlicki et al. 1997). In the largest study puillishcd (Allels 1')92), p"ticnt' 
receiving platinum-bascd cheillotherapy responded more r<lpidly than those 
recciving other combinations but the overali rcspollse rate was similar in the 
t\Vo groups. Howevcr, dose intensity or the two fnnns or chel110thcrapy was 
not asscssed and it is thercforc impossible ta compare the degrees of myelo-
suppression induccd by chemotherapy and thus the capacity of rHEpo to 
overeome il. Patients receiving chemothcrapy of moderate intensity respond 
as well as those not receiving concomitant chemotherapy (Abels 1992). Il is, 
however, probable that more intensive chcmotherapy regimens wOlllcl he 
associated with lower response ratcs. ln particular, rl-iEpo therapy is not 
capable to stimulatc erythropoicsis in the carly pcriod rollowing intensifkd 
]'IL"llIL"lIIHII!J IL"~I)PII~L" II! L"I)lllIIJJhHL"(11i _\)') 
ehcmotherapy with autologous bone marrow transplantation (Link ct al. 
1994 ). 
On the other hand, surgery or complications or ehemotherapy, sueh as 
inflammation, infections or blceding, may have a major ncgative impact upon 
rcsponse (Tablc 2). Chronic or acute blccding is a frequent complication of 
cancer, and this is particularly truc in thrombocytopenic patients, Surgery is 
orten rollowcd by a transient loss of response to rHEpo, not only bccause 
it Illay be complicatcd by significant blond losses, but alsa because posl-
operalive crythropoicsîs is limÎted by the inllamlllatory cffect or surgcry on 
iron Illctabolislll that impairs iron reutilization (J3iesma ct al. 1995). Any 
SUlIrù' nI" in!l;lInm'lIÎnll. hl' il rl'lalL'd [0 slIrglTy, traullla, infectioll or con-
comitan[ disoll .. lL'I"s will in1l'rfcre with response to rllEpo. In particular, 
infections have bccn shown to eause hyporcsponsivcness ta rHEpa in 
paticnts with the anemia of. renal railurc (Danielson ct al. 1995). Inrcctions 
accur frequently in cancer patients receiving chcmatherapy. TIlis will slow or 
totally prevent responsc at the beginning of rHEpo thcrapy, as weil as abro-
gale response wh en the targct Hb Îs bcing maintaincd with lower doses, 
requiring higher doses ta be started aga in. 
FUI/criun,,/ iWI/ deficicl/cy 
Functional iron defIciency is a major factor limiting the efficaey of rHEpo 
therapy ("fable 2). Il is defined as an iron deficit in the functional erythroid 
compartment, the result o[ an imbalance between iron needs in the erythroid 
marrow and iron supply (Fig. 1). This may oCCllr cven in the presence of large 
Iron stores. when storagc iron releasc is Inadequate. Iron requircments arc 
dclermÎncd by the over,,11 level or erythropoietic aClivity and Iron availabil-
ity depends on the levcl or iron stores and their rate or mobilizatial1. FlIIlC-
tiollal Iron deficiency can occur berorc rI-IEpo is startce!, cither becallsc Iron 
stores arc absent (truc iroll deficiency) or hec<luse storagc iron rcleasc is 
illlpaircd. ~I typical reature or the tlllclllia or l'hrunie disorders (Fillel ct al. 
II)~I)). Il can alsu dcvclop in the course 01" crythropoietin thcrapy when iron 
stores becol11e progressively cxhaustcd or, more freqllcntly, when the in-
creased iron necds of an cxpanding crythroid marrow cannot be malehcd by 
slll1icient mobilization of orten enlarged iron stores. Indccd, thc vast major-
ity of rcnal failure patients trcatcd \Vith rHEpo develop funetional iron 
c1elicicncy that limits seriously their crythropoietie respollse (Macdougall 
1999). Although this has not becn speeifically examincd in cancer patients 
treated \Vith rHEpo, there is every reaSon to bclieve that its prevalence is 
very high in this sctting as weil. 
Functional iron dcficiency is best diagnoscd by a perccntage of reticulo-
cytcs with a helllogiobin content lü\Vcr than 26 pg (Brugnara ct al. 1994; 
_,II 1.IH.-'gUlIl 
J\latTophagl's l'I;l.~m!l i\!:u'nm 
(fl'rritin) (Iransft-.,.-ill) (hl'lnn~lnhin) 
Normal (W ~ 7 t J l ' ".' .......... -+~ 
Anemia of chronic disOI-der 
.. (!!)f---D .. o 
d-luEpo 
.. @ .. D.O 
ACD + rHuEpo 
.. (!!)f---O.O 
Fig. 1. Iron mctabolism in various conditions illustratcs l"ullctional iron dcflcicncy 
A. Normal: whcn senescent l'cd ecUs are phagocytoscd (1) hy macrophages, iron is 
rccyclcd intü a transit pool (2); part is storcd as fcrritin (halched arca) (3) and the 
rest is rclcascd (4) to plasma transfcrrin (5); iron is then tab:[1 up (6) by the erythroid 
marrow (7) to producc normal rcd cclls. Iron supply (4) hy storagc cells matches iron 
ùcmand (6) by the crythroid marrow and transfcrrin rcmains adcquatcly (20--40%) 
saturatcd (black lilting) by iron (5). 
B.Ancmia oIc!Jrollù' disort!cr (ACfJ): iron rclèasc by l1lacrophag~s is bl{)ck~d ;uld 
!1wrc iron is storcd as rerritin within thesc cc Ils. Imn supply GIn no longer match iron 
d~ll1anù by the erythroid marrnw: transfclTin saturation dcercascs «2()<Xl), the 
erylhmid Illarrow hccolllcs fUIlL"ion;dly iroll dclil'iclll :lml IlCW rcd l'cils arc 
!typochromie. 
C. '[i-c(/{/JH'llf LVitll rliIlE/)(): the erythroiù l1larrow cxpands upon intense stimulation 
by erythropoietin. Its increascd dcmanu l'or irol1 canllot he lllatched by st{lr;lg~ iron 
n:Jcasc: transfcrrin saturation decn:;lscs «20%), the erythroid lll;llTOW ht.'c()ll1~s 
!"ullctionally iron delicient and Ilew reu cclls art.' hypochromic. 
D. J\CD treated lvi/II r/fllf:/}(): impaireJ' iroll suppl)' and Încreaseu iron <.kmand 
combine to Jecrcasc transferrin saturation and cause fUllctional iron ddiciency 
l'JL'lhelHlll ul rCS[hlllSC lu cl'ylllropo.clln ~ Il 
I3rugnara IlJlJH) or a percentagc 01" hypochromic red cclls grcatcr 1han lCrx) 
(Macdougall ct al. 1992), both paramctcrs calculatcd by some automatccI 
hcmatologic ccli counters. Altcrnatively, it can also be suspected when trans-
fcrrin saturation falls below 20%. On the other hand, serum ferritin is of very 
limited value, because it only gives an evaluation of iron stores without pro-
viding any hint on how these stores can be mobilizcd (Kooistra et al. 1991). 
Bccausc therc is somc concern that tumor cclls may nced iron for optimal 
growth (Weinberg 1996), routine iron supplemcntation of aIl cancer patients 
receiving rHEpo is n01 rccommcndcu. Thc saille is truc roI' oral as weil as 
intravcnOlIS iron supplcmentation. I-Iowevcr, this ShOlIlu be balanced with the 
J"acl Ihal transrusion or OIH.' rcd hhHH.1 ccII unit a[so providcs a large amollllt 
(200mg) of iron. Iron supplements should be given when absolu te iron 
delicicncy is suspeclcd, i.e. whcn serum I"crritin is helow 40-100~tg/L. a level 
assocÎatcd with absence 01" iroll stores in the anemia 01" chronic disorders. 
Othcrwise, iron supplements should be givcil whcn the transferrin saturation 
is h<:low 2()(}\, or the perccntage of hypochromÎc red cells greater tl1(ln IOcX, 
and Illay he discolltillucd when they stahilize within the normal range, The 
experience in iron-rcp1ctc renal failure patients has clcarly indicated that oral 
iron supplcmcntation is only marginally superior ta no iron (Macdougall ct 
al. 1996) but that intravenous iron both substantially improves response when 
rHEpo thcrapy is instituted (Macdougall ct al. 1996) and allows consider-
able (in the order of 40%) reduction in rHEpo dose requirements during the 
maintenance phase (Fishbane et al. 1995; Besarab et al. 2000). The safety 
profile (Sunder-Plassmann ct al. 1997) of iron saccharate, an iron complex 
ta ken up by reticuloendothelial cclls, makes it the preferrcd intravenous com-
pound ovcr iron dcxtran (more anaphylactic reactions) or iron gluconatc 
(more toxic;ty duc to frce iron rclease) (Drucke ct al. 1997). Iron usage has 
Ilot been cnergetic<llIy pllrsllcd in clinical trials of rl-IEpo in cancer patients 
and \Vas generally Icft to the discretÎoll of the individual investigator. This 
\Vas based on the I"alse perception that cancer patients do not rcally nced iron 
togcthcr \Vith crythro]loictin hecillIse theÎr iron stores (ferritin) arc not 
dccrcased. In addition, iron has only becn givcn orally, a mcthod proved to 
be of littlc cfficacy in renal failure patients and p'resumably cvcn Jess effec-
tive in callcer patients bccause of" impaircd iro!1 absorption, anothcr charac-
teristic of the 'Inemia of chronie disorders (Scars 1'!02; Means et al. l,!l)2). 
The crtlcacy of Înlravcllous iro!1 arter I"ailure of oral iron fo correct fUl1ctional 
iron deficicncy and improvc ancmia has becn well documcnlcd in juvenilc 
chronic arthritis. another form of ancmia of chronic disorder (Martini ct al. 
1994). Although this has not bcen formally studicd in the anemia of cancer, 
intravenous administration of IOOmg clemcntal iron every weck or 200mg 
evcry [lther weck will cnsure the best utilizat;on of any given dose of rHEpo. 
Future c1inical trials should investigate the use of intravenous iron in cancer 
patients treated with rHEpo to demonstratc greater cfticaey and/or lowcr 
crythropoictin rcquircl11cnts, 
272 y. Beguin 
Predictive modcls 
IntroductiO/l 
I3ccause response rales vary considerably 31110ng patients trcatcd similarly 
and c1iliical cfficacy cannat be assessed before wceks of treatment, identifi-
cation of carly predictors of rcsponse would be of major interesL The use of 
such prognostic factors of rcsponse eould help provide the bene lits of 
rI-IEpo thcrapy ln as many <Incmic cancer patients as possible. \Vhile avnid-
ing prolongcd illelTcclivc LIse nI' ail L'xpcllsivL' Illcdicatioll. 
J\ prL'dicti\'L' algllritlllll {lI' l"l'SI){lllSL' (n rlll'~p{l Il;\S firsl hl'L'II propos .... d 
in the SètlÎng of the anèlllia associatcd \Vith !"L'ilal l'ailure «(·ïg. 2) (Beguin ct 
;11. 1 ()t):1h). The hesi predictioll hy hasèlillL' parallleicrs only \Vas ()hlaillL:d \Vith 
prctrcatmcnt soluble transfcrrin rL'ceptnr (sTfR) and Ilhrinogcll. Serum sTfR 
rL'presents a quantitative mcaslirc of crythropoiL'lic activily (J-Illchcrs et al. 
19l)() and is also incrc;lsed wllèn fllnctinnal inm dèlkicllcy dèVeh)ps (Skikllc 
ct al. !l)l){)). Il CIIl 1l0W he Illèasllred hy several cOllllllcrcial illlllllliloassays. 
There \Vas a 100% response rate when both sTfR anu librinogen were low, 
versus only 29{Yo whcn they were bath high, and 67% whcn one was low and 
the other high, Changes of sTfR after 2 weeks of treatment \Vere also pre-
dictive, When the 2-week sTfR increment was 2:20%, the response rate \Vas 
96%. When sTfR increment was <20%, the rcsponse rate \Vas 100% whcn 
bascline sTfR was 10IV and fibrinogen normal, 12% when baseline fibrinogen 
was elevated and 62% when baseline fibrinogen was normal but basclinc 
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Fig. 2. Prediction of rcsponsc to rHuEpo in the ancmia of rena! fai!urc by baseline 
sTfR (an indicator of functional iron dcticicncy), baseline librinogcn (a paramctcr of 
inflammation) and the 2-wk sTfR incrcmcnt (a markcr of incrcasing crythropoietic 
activily) (Beguin ct al. j993b) 
Prediction uf rcspunst: tu crythropuictill 27.1 
erythropoietic fesponse (changes of sTfR Icvels), subclinical inOammation 
(fibrinogcn) and funetional iron deiiciency (bascline sTfR), 
Baseline parameters 
Theoretically, canccr patients with a defeet in their capacity ta produce Ero 
would be more likely tD respond to rHEpo than those with adcquate serum 
Epo \cvcls l'or their dcgrcc or anemia. As Epo lcvcls must he intcrrrctcd in 
relation 10 thc dcgrcc or anèlllia, the ratio or observcd-to-prcdictcd Epo 
kn'Is ( )/1' r;ltitl) I"q)]"l'Sl'lltS a hetlL'r ilSSL'SSlllL'lIl ilf thL' iH.kqllil\:y or !':po pro-
duction (Beg.uin ct al. lt)l)]a). Bascd un rcgrcssioll cquationsobtaincu in rcf-
lTCllCC sllh.iccts. prcdictcd log (I:po) values Gill he dcrivl:d for cach I-Ict, and 
Of!' ratius or obscrved-to-prcdictcd values l'ail he ealculatcd (lJ5 1X) con Ii-
dCllCC limits O}\O-1.20) (Beguin ct al. 1 l)l):'a) , ln patients with hcmatologic 
Ill;dignilllcÎcs, il llas hL"l"1l ohscrvcd th;ll lu\\' h;lsclinc scrUIll Epo lcvels 
(I.udwig L't al. !t)l)_I) or dL'Crctlscd ()!l' ratio «'a/zola t:l al. 1 ()l)2) were asso-
ciated \VÎth a significantly higher probability or responsc. This has becn 
conlirmcd in large multicenlcr trials in patients with multiple mycloma or 
non-Hodgkin's Iymphoma (Osterborg ct al. 1991i: Cazzola ct al. 1995). An 
O/P ratio < (),9 was found ta be associated with high response rates, whereas 
patients with an O/P ratio> 0.9 rarely bcnefited from therapy (Cazzola et al. 
1996). However, studies in patients with sol id tu mors have failed ta confirm 
such a consistent predictive value of baselinc Epo even when Epo defieieney 
was demonstrated in ail or part of the patients (A bels 1992; Cascinu et al. 
1994: Platanias et al. 1991: Ponchio et al. 1992: Oberhol1 ct al. 1998), although 
a study aiming. at preventing ancmia in patients with ovarian carcinoma 
undergoing platinum-bascd cheillotherapy showed a trend for lowcr trans-
rusion needs in those with an O/P ratio < OB (ten Bokkcl Huinink et al. 1998). 
Of importancc, in patients treatcd with chcmotherapy, serum Epo should 
be evaluated jus! prior to chclllothcrapy for its Interpretation to be valid 
(Fig. 3). Indecd, without any change in hematocrit, serum Epo may he inap-
propriatcly clevatcd in the two weeks artcr clwlllotherapy compared to 
prc-chL'motherapy valuL's, most probahly hecause myelosuppression Ihell 
decreases Epo utilization by targct cells (Beguin ct al. lt)t)l: Cazzola cl aL 
199R). Thercl'ore, it cannat be cxcludcd that the failurc ta predict response 
in solid tlllllor patients may jllst be rclated to an inadequate timing of serum 
Epo sampling, 
Other basclinc paramcters have been examined as possible predictors of 
rcsponse. Prctrcalmcnl hematocrit is of course an important factor whcn 
rHEpo is givcn for the prevention of anemia (Crawford et al. 1994) but is 
no longer hclpful when it is given after anemia is weil established (Ludwig 
et al. 1994). Other measurements 01' erythropoietic activity, such as the retic-
ulocytc count or sTfR levels were no! predictive of rcsponse (Ludwig ct al. 
ni Y. Beguin 
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Fig.3. Changes in serum Epn, Hb and sTfR arter a chclllothcrapy cycle. ChclllOthcr-
apy transicntly causes ~1Il incrcasc in scrUlll Epo Icvels 1hat is dispropurlÎollall' 10 Ihe 
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Fig. 4. Prediction or rcsponse t'o rlluEpo in the ~llll'll1i;1 or e;lllcer hy the wl'Ck .2 
absolutc serum Epo Icvcl and the 2-wk Hb Încrelllcn! (Ludwig ct al. !094) 
1994). Only large doses of rHuEpo can overcome the strong inhibition of ery-
thropoiesis induccd by such cytokines as IL-l, TNP-a and lION-y. Ludwig ct 
al. (1994) examined the possible predictive values of serulll levcJs of these 
cytokines, but the results were disappointing. l11is is not entirely surprising 
sincc serum lcvc1s of thesc cytokines may not he relevant. whcreas local 
intramcc1ullary levcls may be mllch more important but are very c1ilïicult to 
ev:du<ltc. 
j1rL'dlCII{111 (li rL' ..... pO!l~L' 10 lï'.\ IIlJ'UlhlIL'11l1 
_/.' 
' .. "orly ch(/nge.\' ;,/ crythrojJoielh' f}(fltlll/clers 
Early changes in parameters of erythropoietic aetivity observcd after two 
weeks of trcatment could bc more informative. A rapid elevation of 
hemoglobin levels often predieted a good probability of 1ater response 
(Ludwig et al. 1994; Henry ct al. 1995; Cazzola et al. 1995). An increase of 
reticulocyte counts by :o-40000/rtl from baseline to week 2 or 4 appeared ta 
he predictive or rcsponsc hut ils discriminativc power was wcak (Henry 
ct <lI. ]t)l)5). In several siudics, hCl11atologic rcsponsc 10 rl-lEpo \Vas strongly 
;Jssociakd \Vith carly incrcascs or sTfR Icvcls arter 1-2 wccks or trcalment 
(l'<,,,chio ci al. l'J')]: Can.ola cl al. l')'!::>. 1')%). Ludwig ei al. (l'!'!,)) con-
ductèd the mosl thorough <In;llysis and round thal incrcascs of hcmoglobin, 
sTfR and reticulocytes. as weil as decrcases of serum Epo, ferritin, iron, 
C-rcactivc prolcÎn or ncoptcrin artel" t\Va wccks \Vere ail correlatcd with 
rcsponsc. 
Predictive algorit//Ills hllset! ()JI early changes 
Various models have sought ta combine the predictive power of several 
parameters. ln a study including similar numbers of patients with sol id tumors 
or hematologic 11lalignancies (Ludwig ct al. 1994), if after 2 weeks of therapy 
Epo \Vas >lOOmU/ml and hemoglobin had not incrcased by atleast O.5g/dL, 
thcre \Vas a 94~) probability of unrcspollsivcncss; otherwise, rcsponsc was 
likely in 80% of the patients. ]j'serum Epo was <IOOmU/ml and hemoglobin 
concentration had increased by :0-0.5 g/dL, the probability of responses was 
lOOf};): othcrwisc. the probabilîty of failurc \Vas 62(X). Howcvcr, 34/80 patients 
did Ilot faIJ into any of thcse {wn categories and, thus, prediction was valid 
onl)' in a litth.:: more lhan hall' of them. The predictive valuc of a dccrcasc in 
st:rum Epo Icvels may have 1wn cxplanations. Endogenolls serum Epo could 
{kc'rcase as the hcmatocrit rose in responders. but the magnitude of the 
hl'Illalocrit changes by 2 wceks seclllcd to he 100 small for that. On the other 
band, Epo coulLi he lItilized by an expunding crythroid marrow or conversely 
accumulatc in non-respondcrs, but it cannat be excJucied that these later 
patienls were rccciving more intensive chcmothcrapy than others and thus 
he more likcly ln have inappropriate incrcases of cndogcnous serUIll Epo 
values (Beguin et al. 1991; Cazzola et al. 19ljS). AlternativcJy, a serum fcr-
ritin value :o-400ng/ml after 2 weeks predicted for failure in 88% of the cases, 
whereas serum ferritin levcJs <400ng/ml predicted for suceess in 72% of the 
cases. However, the specifie cutpoint of 400 ng/ml cannat be extrapolated ta 
other patients. because it depends so I11uch on the previous transfusion 
histor)'. 
ln a subset of patients from a large Illulticcnter stucly (Abels 19lJ2), SOllle 
prcdiction of respOllSC could he deri"ed l'rom changes obscrvcd in rcticulo-
27() y. Ikguin 
cytcs and IlCmoglobin l'rom basdinc to \Veek 2 or lhe:rapy (Fig. 5) (Henry èl 
al. 1995). Among patients not recciving chemotherapy (Fig. SA). the response 
rate was poor when the 2-week increment of hcmoglobin leve! was <0.5 g/dL. 
but it was excellent when the hemoglobin level or reticulocyte cOUIlI 
illcreased by ?0.5 g/dL or ?40000/flL. respectively. The predictive power of 
these parameters \Vas much Icss substantial \Vhen the hemoglobin inereased 
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2-wk H b increment > 0.5 < 0.5 (g/dL) 
2-wk retic increment >40 < 40 > 40 <40 (X103/~L) 
Fig. 5. Prediction of rcsponsc 10 rHuEpo in the anemia of cancer by the 2-wk Hb 
<Ind rcticulocyte incrc111cnls (Henry et al. 1995). A good prediction can bc obtaincd 
in p;11iclll~ Ilot rccciying ChclllOlhcrnpy (1\) hut not in tbosc rccl·ivill.1! ChClllO-
Pl"nJiclilll1 01 I"L'SJhll1Sl' III L'rylllrnpoÎL'111l 2/1 
hy 2':0.5 g/d L but (Ile: n:ticulocy(c dcvatioll \Vas smalll:r. i\dequalL: predictioll 
of respollsc could not be providcd 011 the basis of Hb and reticulocyte changes 
in patients rccciving concomitant chemothcrapy (Fig. SB). Although some 
improvcment in foreensl could be obtained in patients incrcasing thcir hcmo-
globin by ? 1 g/dL after 4 weeks of trcatment, predicting response on the basis 
of lhe response itself may appear 10 be trivial. 
Predictive algoritl/1J/s !Jased 011 a combillalioll of 
!Jase/ille jJaral11elcrs und carly changes 
A combination or bascline parameters and carly changes obscrvcd artcr 2 
weeks of rHEpo may proviLle unothcr uscrul approach. Among cvaluablc 
patienls lreated in a large mulliccnler sllldy (Cazzola et al. 1995), the failllre 
rate was almost 90(X) whcn hasclinc serum air Epo was highcr than 0.9 or 
whcll Serum O/f> Epo \Vas Iess lhan O.l) but the hcmoglobin incrclllcnt by 
wcek 2 \Vas «Ug/dL (Fig. 6). Onlilc other hand, the slleeess raIe \Vas arollnd 
90(Yo whcn basclinc serum air Epo was less than 0.9 and hcmoglobin 
illcrcascd by :2:0.3 g/d. Similar nndings were obtaincd in a smallcr study in chil-
dren with sol id tumors: an O/P ratio <1.0 at bascline and a hemoglobin incre-
ment >0.5 g/dL after 2 weeks wcre associated with higher response rates 
(Leon et al. 1998). In another large single-center study (Cazzola ct al. 1996), 
the combined use of baseline serum Epo and the 2-week inerement of sTfR 
praved to be very powerful (Fig. 7). Only 18% of patients with a baseline 
serum Epo greater than lOOmU/ml respanded to treatment, and only 29% 
responded whcn the baseline serum Epo was <100mU/mL but the 2-week 
sTfR increment was less lhan 25%. On the olher hand, the rcsponse rate was 
06{Xl among patients with a low bascline serum Epo and a substantial sTfR 
clcvation. 
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Fig. 6. Prediction of rcsponsc to rHuEro in the anemia associatcd with 1ymphoma 
or multiple myclom<l by thc basclinc obscrvcù/predictcd serum Epo ratio and the 
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Bascline serum Epo > 100 < 100 
2-wk sTfR incromont < 25 > 25 
(mU/ml) 
(%) 
Fig. 7. l'rL'dielÎull uf rL'SpUIl:-l' III rlllll':po ill IhL' :IIIL'IlÙ:1 Ill' e;llll'L'1' hy Ihe h;lSL'liIIL' 
serulll Epo kvel and the 2-wk sTfR increll1enl (Cazzola d al. 19(6) 
ApplicalJili/y of prcclic/ivc flic/ors 
Therc arc a number of theoretical reasons why some or aU of thcse paramc-
ters might not be of value in certain situations (Table 3). While cvaluation of 
endogenous Epo production may be relevant in various forms of anemia. it 
is of no interest in subjects in whom the aim of rHEpo therapy is to prevent 
an ancmia that is not yct present, in those in whom bctter tumor oxygena-
tion before radiotherapy or induction of fetal hcmoglobin is sought, or in 
disorders charactcrized by universal Ero deficiency. Even among cancer 
patients, whereas low baseline serum Epo levels or clecreased observed-to-
predicted Epo levcIs (O/P ratio) were associatcd with a significantly higher 
probabilily of rcsponse in pntients with hem<ltologic malignancies (Ludwig 
et al. 1994; Osterborg ct al. 19%; Cazzola ct al. 1995. l')%).this \Vas lIslially 
not the case in patients \Vith solid tUlllors (Abels 19<)2; Caseinll ct al. 19
'
)4). 
On the other hand., hCllloglobin incremen1s aller 2 weeks or treatment may 
be of value in steady statc patients, but arc or liUle hclp in transrused patients 
anù in those in whoill rl-IEpo is inlcndccl to prevenllhe occurrence or severe 
ancmia but cannat avert some dccrcase in hcmoglobin incluccd hy phle-
botomy or myelosuppressivc lrcatments. Finally, changes in paramctcrs 
directly rdlccting erythropoictic activity., i.e. rcticulocyte counts and sTfR, 
may be the mos1 appropriatc. I-Iowcver., changes in rcticulocyte counts may 
sim ply reOect output of shift reticulocytes and not true expansion of ery-
thropoiesis, and often have not been found to be a goocl indicator of response 
(Beguin et al. 1993b; Ludwig et al. 1994). Although sTfR levels represent the 
best quantitative measurement of total erythropoictic activity, they may also 
increase secondary to functional iron dcficieney (Hucbers ct al. 1990). In 
addition, partieularly in patients treated with chemotherapy, the timing of the 
evaluation of these paramctcrs relative to chcIl10therapy may he critical l'or 
their interpretation. For instance, Illcilsuring serum Epo artel' c!lclllotherapy 
Prediction of n.:sponse tn L'rythropoiclin 27Y 
T:.thlc 3. Theorelical value (~ies :::: probably of value; no :::: probably of no value) of 
potcntial prcdictors of re~ponsc to rl-IuEpo in vminus scttings according to the indi-
cation for thcrapy (sec text for discussion) 
Baseline 2-wk Hb 2-wk 
Epo or increment retie/sTfR 
o/r ratio incrcment 
1. l'reventi()n of ilncllli:l 
• AU!O]OgOllS hlond dOllatioll No No Ycs 
• :\djU\':llll 11'l':llllll'lll fol' phkhtlllllll,\' Nu No 'l'L's 
• l'cri:-uq.!,L'l'Y No No ( t) No (1) 
( ïlClll\ lllln:!py (plalllll'll) l'cs (2) Nu No 
2, Correclion of llntransfuscd ,lllemia 
• AIDS, illllillllmaiury ùiseasC's, cancer, Yes (2) Ycs Ycs 
MDS, organ transplantation 
• Chcmothernpy (ongoing) Yos (2) Yes (3) Yes (3) 
l. Reduction in transfusion rcquirclllC'nts 
• AIDS, inOammatory discases, cancer, Yes (2) No Yes 
MDS, organ transplantation 
• Chcmotherapy (ongoing) Yes (2) No Yes (3) 
• Prcmaturity No (4) No Ycs 
• Aliogencic stem ccli transp!"lIllatioll No (4) No No 
4. Miscellaneous 
• Radiothcrapy No Ycs Ycs 
• Orthostatic hypotension No Yes Ycs 
• Inuuclion of fetal }-Ih No No No 
1:]10'-:; crylhropoÎclin: O/P ":]10 =: ratio of ohservcd-to-11rcllicled Epo; Ilh:::: hellHl-
g!nhin; relie;:::::; relicu!oeyles; sTfR = soluble lransfcrrin reccplor. 
(1) Treatmenl 100 short 10 he 1110diiied hy changes in erythropoidic parameters. 
(2) Epo ddîciency in some forms of GlllCer (lymphoméJ, mycloma, SOIllC MDS) and 
dlL'lllotherapy (cispl"ltin). 
(l) Timing of samplc for measureJl1cnl of predictor may he critical (sec text). 
(--1-) Not ;1 l'cal prcdiclol' hCC:lllSl' I~p{) I..kllcicncy is ohscrved in virtua!ly a[1 paticnts. 
may yield e1cvatcd levels compared 10 pre-chcmothcrapy values, wÎthout any 
change in hcmatoerit (Beguin et al. 1991). 
COI1C'/[{siOll 
Several algorithms have bcen proposcd l'or patients with the ancmÎa of 
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Predicti()1l uf rL'spoIlSL' [u ery[hropoietin 2XI 
who will respond) and spccilicity (how weil the algorithm exc\udcs ail those 
who will I"ail), and thus their ove rail cflieacy, vary eonsiderably. ln the study 
eonduetcd by Ludwig (Ludwig ct al. 1994), when one trics primarily to idcn-
tif Y non-responders instead of rcsponclcrs, scnsitivity and ovcrall aeeuraey 
ean be inercasccl from 42')(, and 70% to 76% and R6%, rcspcetivcly. Ovcrall 
,rccuracy is not improvcd by doing so in the study eonuuetcd by Henry 
in p;ltil'Ilts rccciving chclllothl'rapy. hcc:luse cnhallecd sCllsÎtÎvily (S,VXI) is 
cOlllpens;\ted by diminished .''ipceilicity (52~XI). The positive predictive value 
(prohahitity or responsè in thuse predicted tu rl'spond) or the algorithms is 
lIsu;dly hl'ttcr tl1:111 their I1cg:llivl' predictive valuc (prohahility of" failurc in 
those prcdictcd to rail). 
The hest algorithms appear 10 be those combining an assessment of the 
adcquacy of cndogenolls Epo production (al !cast in hcmatologic malignan-
cics) togcther with somc carly inc.licators of crythropoictic marrow rcsponse 
(changes in hellloglohin or sTfR). The following scheme can he proposed in 
practicl.' (Fig. 1-\). Basèlinc serum Epo slJould he IllcHsured at haselinc in 
patients \Vith hematologic malign<lncÎes: trcatment should not be iniliateu 
if cndogenous serum Epo is abovc IOOmU/OlL (or 2000lU/mL in scverely 
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Fig. X. PractÎcal use of algorilhms for prediction of responsc in cancer patients 
trcatcel \Vith rHuEpo. bascd on baselinc cndogcnous Epo Icvel and an carly (2-wk) 
indicator of increased erythropoietic activity. lllC lirst step (baseline Ero) could 
he omitted ill solid tumor patients. The only diffcrcnce bclwecn untransfused and 
[1'.Hlsfused paticnts is tl1at the 2-wk Hb increlllcnt cannol he used in transfusion-
dCj1cll(kn[ p:l[icnh :Ind lllll") 1w rC1l1:WI'r1 h,' lh,' "_\\'L "TD;:> ;PI"'('nl"'" 
2X:2: Y. lkg,uin 
assesscd arter 2 weeks. In untransfuscd paticnts. if the I-Ib has incrcasccJ by 
at least 0.5 g/dL, continue trcatment; othcrwisc double the dose and cJclini-
tively discontinue rHEpo aftcr 2 additional wecks if Hb has not incrcascd by 
at Icast 0.3 g/dL. [n transfused patients, if sTfR has increased by at leas! 20%. 
continue treatment; otherwisc double thc dose and dclinitivcly discontinue 
rHEpo after 2 additional wceks if sTfR has not incrcascd by at Icast 20'X,- Il 
is, or course, crilicai lhat ail prevel11ablc causes of failure arc identillcd 
prospcclively and corrcctcd, or L'Isl' no predictive lllodcl will he valid. In P;II'-
ticular this includcs vigorous iron supply and L'ncrgctic Ircalmcnt of inter-
currcnt complications slIch as infections and hlL'L'ding. 
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Chapter XVI 
rhEPO in hcmatopoictic stcm ccII mobiIization, 
transplantation and in-vitro cxpansion 
.\. !\.' h/I'ssoll 
Dcpartmcnt or Pcdintrics. I-Iuddingc University Hospital, Karolinska Institutc. 
Stockholm. Swedcn 
SUlllllwry 
Vnrious hcmatopoictic growth factors and cytokines are being incrcasingly 
studied in the transplant sctting. They arc uscd, not only to accclerate 
haematopoietic recovery after cytopenias but also as mobilizers of stem cells 
in donors, ex vivo expansion of stem cclls and for supportive treatment during 
infections. Ali these new factors, alone or in combination, may contribute to 
improvcd regimcns during transplantation. Bone marrow transplant (BMT) 
or peripheral blood progenitor stem cells transplant (PBSCT) recipients 
have in the pcrioe! following transplantation a frequcnt need for rcù blooe! 
cel 1 transrusions anù. thercron.::, an increased risk or hlood-transmittcd infec-
tions. The ancmia is causcd mainly by myelosuppression arter high-dose 
chcmotherapy but an impaired crythropoictin (EPO) production and an 
inappropriatc EPO responsc Illay also contributc. Sincc recombinant human 
erythropoictin (rhEPO) has bccn established as a trcatment for renal anemia 
il has beell of interest whether trcalmcnt may be of bencllt in the trans-
plantation sctting. So far data do 1101 support any transfusional bencfits with 
the use of rhEPO artcr autologous transplantation. In patients recciving an 
allogran, espccially patients \Vith immune hemolysis arter transplantation, 
rhEPO trealment sec ms 10 accclerate erythroid cngraftmcnt, increasc hcmo-
globin levels, reducc red blood cell transfusions and shorten time to trans-
fusion independencc. Howcver, the optimal dose of rhEPO, the route of 
administration, the most effective combination with other hematopoictic 
growth factors, and in whieh patient populations cost-effective rhEPO 
thcrapy is justificd are still open questions. 
Background 
